The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
Open accessAbstract
// Xinxin Zhu 1 and Jinghe Lang 1 1 Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China Correspondence to: Jinghe Lang, email: langjh@hotmail.com , doctorlangjh@163.com Keywords: soluble, PD-1, PD-L1, tumor immunity, biomarker Received: April 25, 2017 Accepted: May 22, 2017 Published: May 31, 2017 ABSTRACT The membrane-bound molecules programmed death 1 (PD-1) and its ligand PD-L1 (PD-1/PD-L1) belong to the immune checkpoint pathway. PD-1 pathway downregulates effector T cells in immune response, thereby causing immune suppression. Recent studies have revealed that membrane-bound PD-1 and PD-L1 also have soluble forms. These soluble forms increase the complexity and diversity of the composition and function of the PD-1/PD-L1 signaling pathway. However, the exact roles of these molecules remain unknown. The objective of this systematic review was to elucidate the biological significance of soluble PD-1/PD-L1 in human cancers and evaluate whether they are potential diagnostic, therapeutic, or prognostic biomarkers. We expect to provide new clues for future research on soluble PD-1/PD-L1 pathway in human malignant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
A family of cytokine-inducible inhibitors of signalling
Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., et al. (1997) · Nature · doi:10.1038/43206 · Cited by 2,066
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889
Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869
Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231486598 · Cited by 848
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Gao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B.-Z., Shi, Y.-H., Xiao, Y.-S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 813
Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
Grunnet, M., & Sorensen, J. B. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.11.012 · Cited by 750
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., & Mandai, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.101 · Cited by 725
Antonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.018 · Cited by 571
Kinter, A. L., Godbout, E. J., McNally, J. P., Sereti, I., Roby, G. A., O’Shea, M. A., & Fauci, A. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6738 · Cited by 513
Wu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X.-G., & Xu, N. (2006) · Acta Histochemica · doi:10.1016/j.acthis.2006.01.003 · Cited by 495
Role of the PD-1 pathway in the immune response
Riella, L. V., Paterson, A. M., Sharpe, A. H., & Chandraker, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04224.x · Cited by 444
Ota, K., Azuma, K., Kawahara, A., Hattori, S., Iwama, E., Tanizaki, J., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0016 · Cited by 435
The PD-1/PD-Ls pathway and autoimmune diseases
Dai, S., Jia, R., Zhang, X., Fang, Q., & Huang, L. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.05.006 · Cited by 354
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Hamanishi, J., Mandai, M., Matsumura, N., Abiko, K., Baba, T., & Konishi, I. (2016) · International Journal of Clinical Oncology · doi:10.1007/s10147-016-0959-z · Cited by 351
Frigola, X., Inman, B. A., Lohse, C. M., Krco, C. J., Cheville, J. C., Thompson, R. H., Leibovich, B., Blute, M. L., Dong, H., & Kwon, E. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0250 · Cited by 345
PD-1 and its ligands are important immune checkpoints in cancer
Dong, Y., Sun, Q., & Zhang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.13895 · Cited by 334
Rossille, D., Gressier, M., Damotte, D., Maucort-Boulch, D., Pangault, C., Semana, G., Le Gouill, S., Haioun, C., Tarte, K., Lamy, T., et al. (2014) · Leukemia · doi:10.1038/leu.2014.137 · Cited by 322
Antagonists of PD-1 and PD-L1 in Cancer Treatment
Lipson, E. J., Forde, P. M., Hammers, H.-J., Emens, L. A., Taube, J. M., & Topalian, S. L. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.013 · Cited by 306
Role of PD-1 in Regulating T-Cell Immunity
Jin, H.-T., Ahmed, R., & Okazaki, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_116 · Cited by 305
Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity
Gianchecchi, E., Delfino, D. V., & Fierabracci, A. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.05.003 · Cited by 270
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
Homet Moreno, B., & Ribas, A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.124 · Cited by 245
Chen, Y., Wang, Q., Shi, B., Xu, P., Hu, Z., Bai, L., & Zhang, X. (2011) · Cytokine · doi:10.1016/j.cyto.2011.06.004 · Cited by 243
Cutting Edge: A Soluble Form of CTLA-4 in Patients with Autoimmune Thyroid Disease
Oaks, M. K., & Hallett, K. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5015 · Cited by 239
Wan, B., Nie, H., Liu, A., Feng, G., He, D., Xu, R., Zhang, Q., Dong, C., & Zhang, J. Z. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8844 · Cited by 233
PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo
Chikuma, S., Terawaki, S., Hayashi, T., Nabeshima, R., Yoshida, T., Shibayama, S., Okazaki, T., & Honjo, T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900080 · Cited by 231
Alternative splice variants of the human PD-1 gene
Nielsen, C., Ohm-Laursen, L., Barington, T., Husby, S., & Lillevang, S. T. (2005) · Cellular Immunology · doi:10.1016/j.cellimm.2005.07.007 · Cited by 226
Differential binding properties of B7-H1 and B7-DC to programmed death-1
Youngnak, P., Kozono, Y., Kozono, H., Iwai, H., Otsuki, N., Jin, H., Omura, K., Yagita, H., Pardoll, D. M., Chen, L., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01257-9 · Cited by 209
Finkelmeier, F., Canli, Ö., Tal, A., Pleli, T., Trojan, J., Schmidt, M., Kronenberger, B., Zeuzem, S., Piiper, A., Greten, F. R., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.002 · Cited by 204
Park, H. J., Park, J. S., Jeong, Y. H., Son, J., Ban, Y. H., Lee, B.-H., Chen, L., Chang, J., Chung, D. H., Choi, I., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401936 · Cited by 201
Nivolumab: Targeting PD-1 to Bolster Antitumor Immunity
Brahmer, J. R., Hammers, H., & Lipson, E. J. (2015) · Future Oncology · doi:10.2217/fon.15.52 · Cited by 199
Zhang, G., Hou, J., Shi, J., Yu, G., Lu, B., & Zhang, X. (2008) · Immunology · doi:10.1111/j.1365-2567.2007.02723.x · Cited by 192
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
Qin, T., Zeng, Y.-D., Qin, G., Xu, F., Lu, J.-B., Fang, W.-F., Xue, C., Zhan, J.-H., Zhang, X.-K., Zheng, Q.-F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5583 · Cited by 191
New immunotherapies targeting the PD-1 pathway
Chinai, J. M., Janakiram, M., Chen, F., Chen, W., Kaplan, M., & Zang, X. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.06.005 · Cited by 189
McClanahan, F., Hanna, B., Miller, S., Clear, A. J., Lichter, P., Gribben, J. G., & Seiffert, M. (2015) · Blood · doi:10.1182/blood-2015-01-622936 · Cited by 188
PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises
Massari, F., Santoni, M., Ciccarese, C., Santini, D., Alfieri, S., Martignoni, G., Brunelli, M., Piva, F., Berardi, R., Montironi, R., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.013 · Cited by 180
PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
Ruf, M., Moch, H., & Schraml, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.30077 · Cited by 179
Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer
Qing, Y., Li, Q., Ren, T., Xia, W., Peng, Y., Liu, G. L., Luo, H., Yang, Y., Dai, X. Y., Zhou, S.-F., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s75152 · Cited by 179
Wang, L., Wang, H., Chen, H., Wang, W.-D., Chen, X.-Q., Geng, Q.-R., Xia, Z.-J., & Lu, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.5682 · Cited by 179
Okuma, Y., Hosomi, Y., Nakahara, Y., Watanabe, K., Sagawa, Y., & Homma, S. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.023 · Cited by 176
Nagato, T., Ohkuri, T., Ohara, K., Hirata, Y., Kishibe, K., Komabayashi, Y., Ueda, S., Takahara, M., Kumai, T., Ishibashi, K., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1987-x · Cited by 160
Wong, R. J., Ahmed, A., & Gish, R. G. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.01.005 · Cited by 153
Soluble B7-H1: Differences in production between dendritic cells and T cells
Frigola, X., Inman, B. A., Krco, C. J., Liu, X., Harrington, S. M., Bulur, P. A., Dietz, A. B., Dong, H., & Kwon, E. D. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.11.001 · Cited by 146
PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
Dolan, D. E., & Gupta, S. (2014) · Cancer Control · doi:10.1177/107327481402100308 · Cited by 145
Soluble CD86 Is a Costimulatory Molecule for Human T Lymphocytes
Jeannin, P., Magistrelli, G., Aubry, J., Caron, G., Gauchat, J., Renno, T., Herbault, N., Goetsch, L., Blaecke, A., Dietrich, P., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00030-3 · Cited by 134
Zhang, J., Gao, J., Li, Y., Nie, J., Dai, L., Hu, W., Chen, X., Han, J., Ma, X., Tian, G., et al. (2015) · Thoracic Cancer · doi:10.1111/1759-7714.12247 · Cited by 127
Kandalaft, L. E., Powell, D. J., & Coukos, G. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-157 · Cited by 127
Zheng, Z., Bu, Z., Liu, X., Zhang, L., Li, Z., Wu, A., Wu, X., Cheng, X., Xing, X., Du, H., et al. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.1000-9604.2014.02.08 · Cited by 125
Sorensen, S. F., Demuth, C., Weber, B., Sørensen, B. S., & Meldgaard, P. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.08.001 · Cited by 115
Inhibition of Lactate Dehydrogenase Activity as an Approach to Cancer Therapy
FIUME, L., Manerba, M., Vettraino, M., & Stefano, G. D. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.206 · Cited by 100
Ge, Y., Hong, X., Ju, S., & Zhang, X. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.03.010 · Cited by 96
Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis
Lee, J. H., Zhuang, Y., Wei, X., Shang, F., Wang, J., Zhang, Y., Liu, X., Yang, Y., Liu, L., & Zheng, Q. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.10.028 · Cited by 83
Takahashi, N., Iwasa, S., Sasaki, Y., Shoji, H., Honma, Y., Takashima, A., Okita, N. T., Kato, K., Hamaguchi, T., & Yamada, Y. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2184-6 · Cited by 83
Geng, H., Zhang, G., Han, X., Yuan, Y., Li, D., Zhang, H., Qiu, H., He, Y., & Feng, Z. (2006) · International Journal of Cancer · doi:10.1002/ijc.21795 · Cited by 81
He, X., Xu, L., & Liu, Y. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00086.x · Cited by 81
PD-1 and PD-L1 antibodies for melanoma
Tsai, K. K., Muñoz, I. Z., & DAUD, A. I. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.983409 · Cited by 81
Cheng, H.-Y., Kang, P.-J., Chuang, Y., Wang, Y., Jan, M., Wu, C., Lin, C., Liu, C., Liaw, Y., Lin, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095870 · Cited by 75
Cheng, S., Zheng, J., Zhu, J., Xie, C. L., Zhang, X., Han, X., Song, B., Ma, Y., & Liu, J. (2015) · The International Journal of Biological Markers · doi:10.5301/jbm.5000170 · Cited by 69
Li, Y., Li, D., Chen, J., Liu, W., Li, J., Jiang, P., Zhao, X., Guo, F., Li, X., & Wang, S. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.8.3451 · Cited by 69
Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma.
Lanxiang, H., Zhang, G., He, Y., Zhu, H.-G., Zhang, H., & Feng, Z. (2005) · PubMed · Cited by 63
Elhag, O. A. O., Hu, X., Zhang, W., Xiong, L., Yuan, Y., Deng, L.-F., Liu, D., Liu, Y., & Hui, G. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.8.4031 · Cited by 61
Han, X., Huang, B., Yuan, Y., Li, D., Han, L., Liu, Y., Gong, W., Wu, F., Zhang, G., & Feng, Z. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2154 · Cited by 61
Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
Zheng, P., & Zhou, Z. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s29325 · Cited by 58
Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-α
Hikita, A., Tanaka, N., Yamane, S., Ikeda, Y., Furukawa, H., Tohma, S., Suzuki, R., Tanaka, S., Mitomi, H., & Fukui, N. (2009) · Biochemistry and Cell Biology · doi:10.1139/o09-015 · Cited by 56
Wang, X., Ni, S., Chen, Q.-Y., Ma, L., Jiao, Z.-X., Wang, C., & Jia, G. (2016) · Cell Biology International · doi:10.1002/cbin.10716 · Cited by 51
Program death 1 (PD1) haplotyping in patients with breast carcinoma
Haghshenas, M. R., Naeimi, S., Talei, A., Ghaderi, A. A., & Erfani, N. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0542-z · Cited by 46
Shin, S., Jeon, Y. K., Cho, Y. M., Lee, J., Chung, D. H., Park, J. Y., & Go, H. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0151 · Cited by 45
Tan, S., Chen, D., Liu, K., He, M., Song, H., Shi, Y., Liu, J., Zhang, C. W.-H., Qi, J., Yan, J., et al. (2016) · Protein & Cell · doi:10.1007/s13238-016-0337-7 · Cited by 43
Safety of pembrolizumab for the treatment of melanoma
Martín-Liberal, J., Kordbacheh, T., & Larkin, J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1021774 · Cited by 36
Pan, X., Li, L., MAO, J.-J., Yao, W., Zheng, J., Liu, M., & Fu, J. (2012) · Oncology Letters · doi:10.3892/ol.2012.966 · Cited by 33
Huang, S., Lin, H., Lin, C., Li, C., Yao, M., Tang, J., Hou, H., Tsay, W., Chou, S.-J., Cheng, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11519 · Cited by 33
Bishop, K. D., Harris, J. E., Mordes, J. P., Greiner, D. L., Rossini, A. A., Czech, M., & Phillips, N. E. (2009) · Cellular Immunology · doi:10.1016/j.cellimm.2009.01.008 · Cited by 30
Pidilizumab in the treatment of diffuse large B-cell lymphoma
Bryan, L. J., & Gordon, L. I. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.942637 · Cited by 22
Zhang, P., Ouyang, S., Wang, J., Huang, Z., Wang, J., & Liao, L. (2015) · PubMed · doi:10.7518/hxkq.2015.05.019 · Cited by 22
Prospects and progress of atezolizumab in non-small cell lung cancer
Vansteenkiste, J., Wauters, E., Park, K., Rittmeyer, A., Sandler, A. B., & Spira, A. I. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1309389 · Cited by 17
The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response
Zatloukalová, P., Pjechová, M., Babcanová, S., Hupp, T. R., & Vojtěšek, B. (2016) · Klinicka onkologie · doi:10.14735/amko20164s72 · Cited by 14
[Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer].
Hamanishi, J., & Konishi, I. (2014) · PubMed · Cited by 8
Cited by
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., & Wang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964442 · Cited by 561
PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Wu, Y., Chen, W., Xu, Z. P., & Gu, W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02022 · Cited by 419
The role of biomarkers in personalized immunotherapy
Sankar, K., Ye, J. C., Li, Z., Zheng, L., Song, W., & Hu-Lieskovan, S. (2022) · Biomarker Research · doi:10.1186/s40364-022-00378-0 · Cited by 111
Ma, L., Wang, L., Nelson, A. T., Han, C., He, S., Henn, M. A., Menon, K., Chen, J. J., Baek, A. E., Vardanyan, A., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.08.020 · Cited by 98
Inhibitory receptor agonists: the future of autoimmune disease therapeutics?
Grebinoski, S., & Vignali, D. A. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.06.001 · Cited by 58
Metadata
- Authors
- Zhu, X., & Lang, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-05-31
- Volume
- 8
- Issue
- 57
- Pages
- 97671-97682
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2618077299
- Cited by
- 303
- References
- 90
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.